Oral · GLP-1 agonist
AZD5004 / ECC5004
16 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
16
Active
2
Recruiting
0
Completed
14
Sites
155
Countries
12
Endpoints
256
Composite endpoints
12
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
14
Phase 2
2
Trials by status
Active, not recruiting
2
Completed
14
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
225
Weight & body composition
16
Glycemic / diabetes
15
Most-measured metrics
Top 20 metrics across this asset's endpoints
AUC₀–∞Safety/PK
48
CmaxSafety/PK
25
Treatment-emergent AEs (any)Safety/PK
18
TmaxSafety/PK
17
Half-lifeSafety/PK
15
Plasma concentration (steady state)Safety/PK
7
Body weight, % changeWeight
5
Serious AEs (any)Safety/PK
4
Body weight, absolute change (kg)Weight
3
Fasting glucose, changeGlycemic
3
HOMA-IR (insulin sensitivity)Glycemic
3
BMI, changeWeight
2
≥5% weight-loss respondersWeight
2
Waist circumference, changeWeight
1
tlagSafety/PK
1
Postprandial glucoseGlycemic
1
C-peptide AUCGlycemic
1
≥10% weight-loss respondersWeight
1
HbA1c, changeGlycemic
1
HbA1c <6.5% achievementGlycemic
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
16 of 16